Gene Expression Profile Selection for Radiotherapy Dose Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the effectiveness of radiotherapy for prostate cancer are limited, leading to ineffective treatments and significant side effects, with a need for better predictive tools to personalize radiotherapy doses and reduce unnecessary therapy costs.
Innovation Solution
A method involving the determination of specific gene expression profiles for immune defense response and T-cell receptor signaling genes, such as AIM2, APOBEC3A, and PDE4D7, to select an optimal radiotherapy dose based on the patient's biological sample, providing a therapy recommendation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiotherapy is administered to treat prostate cancer, then cancer recurrence is reduced, but side effects such as bowel inflammation, urinary incontinence, and erectile dysfunction increase
Solution Approach 1:
The patent applies parameter changes by using gene expression profiles to determine optimal radiotherapy dosing parameters. Different gene expression patterns (e.g., high vs. low PDE4D7 expression) correspond to different recommended doses, allowing the treatment parameters to be customized based on the patient's biological characteristics rather than using fixed dosing protocols
Solution Approach 2:
The patent implements preliminary action by assessing gene expression profiles before radiotherapy administration. This pre-treatment biomarker evaluation allows clinicians to predict treatment response and select appropriate dosing strategies in advance, preventing both ineffective overtreatment and unnecessary exposure to side effects
2Ease of operation
If standard radiotherapy dosing is used, then treatment is simplified, but treatment effectiveness varies significantly with biochemical progression-free survival ranging from 40% to 90%
Solution Approach 1:
The patent transforms the fixed dosing parameter into a variable parameter based on gene expression profiles. By measuring biomarkers such as PDE4D7, AIM2, and other immune response genes, the treatment protocol adapts dosing parameters to individual patient characteristics, resolving the contradiction between standardized simplicity and personalized effectiveness
3Reliability
If gene expression profiling is implemented to personalize radiotherapy, then treatment effectiveness is improved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent extracts specific biomarker information from complex gene expression data by focusing on a defined panel of genes with proven predictive value. Rather than analyzing the entire transcriptome, the method isolates and measures expression levels of specific genes (PDE4D7, AIM2, and others) that have been validated as predictors of radiotherapy response, simplifying the diagnostic process while maintaining predictive accuracy
Data Source
AI summary
The invention relates to a method of selecting a dose for radiotherapy of a prostate cancer subject, comprising determining or receiving the result of a determination of a first gene expression profile for each of one or more immune defense response genes, and/or of a second gene expression profile for each of one or more T-Cell receptor signaling genes, and/or of a third gene expression profile for each of one or more PDE4D7 correlated genes, said first, second and third expression profile(s) being determined in a biological sample obtained from the subject, selecting the radiotherapy dose based on the first gene expression profile(s), or on the second gene expression profile(s), or on the third gene expression profile(s), or on the first, second, and third gene expression profile(s), and, optionally, providing the selection or a therapy recommendation based on the selection to a medical caregiver or the subject.